129 related articles for article (PubMed ID: 11553198)
1. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes.
Witthaus E; Stewart J; Bradley C
Diabet Med; 2001 Aug; 18(8):619-25. PubMed ID: 11553198
[TBL] [Abstract][Full Text] [Related]
2. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes.
Ashwell SG; Bradley C; Stephens JW; Witthaus E; Home PD
Diabetes Care; 2008 Jun; 31(6):1112-7. PubMed ID: 18339977
[TBL] [Abstract][Full Text] [Related]
3. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ.
Bradley C; Plowright R; Stewart J; Valentine J; Witthaus E
Health Qual Life Outcomes; 2007 Oct; 5():57. PubMed ID: 17927832
[TBL] [Abstract][Full Text] [Related]
4. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
Berard L; Cameron B; Woo V; Stewart J
Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
[TBL] [Abstract][Full Text] [Related]
5. Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials.
Polonsky W; Traylor L; Gao L; Wei W; Ameer B; Stuhr A; Vlajnic A
J Diabetes Complications; 2017 Mar; 31(3):562-568. PubMed ID: 28040350
[TBL] [Abstract][Full Text] [Related]
6. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
7. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.
Home PD; Rosskamp R; Forjanic-Klapproth J; Dressler A;
Diabetes Metab Res Rev; 2005; 21(6):545-53. PubMed ID: 16021649
[TBL] [Abstract][Full Text] [Related]
8. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
[TBL] [Abstract][Full Text] [Related]
9. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.
Chatterjee S; Jarvis-Kay J; Rengarajan T; Lawrence IG; McNally PG; Davies MJ
Diabetes Res Clin Pract; 2007 Aug; 77(2):215-22. PubMed ID: 17141354
[TBL] [Abstract][Full Text] [Related]
10. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
11. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
12. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.
McKeage K; Goa KL
Drugs; 2001; 61(11):1599-624. PubMed ID: 11577797
[TBL] [Abstract][Full Text] [Related]
13. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study.
Fonseca V; Bell DS; Berger S; Thomson S; Mecca TE
Am J Med Sci; 2004 Nov; 328(5):274-80. PubMed ID: 15545844
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine versus NPH insulin in patients with type 1 diabetes.
Ratner R
Drugs Today (Barc); 2003 Nov; 39(11):867-76. PubMed ID: 14702132
[TBL] [Abstract][Full Text] [Related]
15. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus.
Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K;
J Pediatr Endocrinol Metab; 2002 Apr; 15(4):369-76. PubMed ID: 12008682
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
Dhital SM; Shenker Y; Meredith M; Davis DB
Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
[TBL] [Abstract][Full Text] [Related]
18. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.
Hershon KS; Blevins TC; Mayo CA; Rosskamp R
Endocr Pract; 2004; 10(1):10-7. PubMed ID: 15251616
[TBL] [Abstract][Full Text] [Related]
19. [Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues].
Hagenmeyer EG; Schädlich PK; Köster AD; Dippel FW; Häussler B
Dtsch Med Wochenschr; 2009 Mar; 134(12):565-70. PubMed ID: 19277932
[TBL] [Abstract][Full Text] [Related]
20. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes.
Rhoads GG; Dain MP; Zhang Q; Kennedy L
Diabetes Obes Metab; 2011 Aug; 13(8):711-7. PubMed ID: 21410859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]